Video Experimental Relacionado
Updated: Jul 16, 2026
15:23
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Ensamblaje in silico del péptido Abeta16-22 del Alzheimer en hojas beta
Sébastien Santini1, Normand Mousseau, Philippe Derreumaux
1Contribution from the Information Génomique et Structurale, UPR 2589 CNRS, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France.
Journal of the American Chemical Society
|September 16, 2004
Resumen
Los investigadores simularon el plegamiento del péptido beta A ((16-22) del Alzheimer, revelando que las estructuras de fibrillas ordenadas requieren agregados más grandes. El proceso de plegado implica la formación de dímeros y la adición de monómeros, progresando a través de un mecanismo que equilibra las alineaciones desordenadas y ordenadas de la hebra beta.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Biología computacional Biología computacional.
- La neurociencia es la neurociencia.
Sus antecedentes:
- Los oligómeros solubles de los péptidos formadores de amiloide están implicados en la toxicidad celular.
- La enfermedad de Alzheimer está asociada con la agregación del péptido beta amiloide.
Objetivo del estudio:
- Para simular el proceso de plegado de los péptidos beta A ((16-22) del Alzheimer.
- Investigar las transiciones estructurales y los estados de equilibrio de estos péptidos durante el plegamiento.
Principales métodos:
- Utilizó la técnica de activación-relajación para simulaciones moleculares.
- Empleó un modelo energético genérico para estudiar el plegamiento de péptidos.
- Analizó las estructuras de energía más baja y sus desviaciones de las conformaciones de las fibrillas.
Principales resultados:
- La estructura de energía más baja prevista coincidía estrechamente con la conformación de las fibrillas (dentro de 1 Å RMSD).
- La estructura de la hoja beta antiparalela se encontró en equilibrio con las estructuras menos ordenadas (fuera de registro y hojas beta mixtas).
- El plegamiento de péptidos se produce a través de la formación de dímeros y la posterior adición de monómeros.
Conclusiones:
- El logro de estructuras de fibrillas totalmente ordenadas requiere la formación de agregados más grandes.
- El mecanismo de plegado implica una transición entre las alineaciones desordenadas y ordenadas de la hebra beta.
- Comprender estas dinámicas de plegado es crucial para la investigación de la enfermedad de Alzheimer.
Videos de Conceptos Relacionados
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...